Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply

Brendan J. McMullan, Asha C. Bowen, Steven Y C Tong

    Research output: Contribution to journalLetterResearchpeer-review

    Abstract

    In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.
    Original languageEnglish
    Pages (from-to)301-302
    Number of pages2
    JournalJAMA Pediatrics
    Volume171
    Issue number3
    DOIs
    Publication statusPublished - Mar 2017

    Fingerprint

    Staphylococcus aureus
    Sepsis
    Pediatrics
    Anti-Bacterial Agents
    Antitoxins
    Therapeutics
    Pediatric Intensive Care Units
    Vancomycin
    Clinical Protocols
    Bacteremia
    Echocardiography
    Epidemiology
    Mortality
    Infection

    Cite this

    McMullan, Brendan J. ; Bowen, Asha C. ; Tong, Steven Y C. / Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply. In: JAMA Pediatrics. 2017 ; Vol. 171, No. 3. pp. 301-302.
    @article{83a87614e8e64da1985ef089d6e28b7a,
    title = "Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply",
    abstract = "In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.",
    author = "McMullan, {Brendan J.} and Bowen, {Asha C.} and Tong, {Steven Y C}",
    year = "2017",
    month = "3",
    doi = "10.1001/jamapediatrics.2016.4689",
    language = "English",
    volume = "171",
    pages = "301--302",
    journal = "JAMA Pediatrics",
    issn = "1072-4710",
    publisher = "American Medical Association",
    number = "3",

    }

    Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply. / McMullan, Brendan J.; Bowen, Asha C.; Tong, Steven Y C.

    In: JAMA Pediatrics, Vol. 171, No. 3, 03.2017, p. 301-302.

    Research output: Contribution to journalLetterResearchpeer-review

    TY - JOUR

    T1 - Targeting Staphylococcus aureus in Pediatric Surviving Sepsis Bundles—Reply

    AU - McMullan, Brendan J.

    AU - Bowen, Asha C.

    AU - Tong, Steven Y C

    PY - 2017/3

    Y1 - 2017/3

    N2 - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.

    AB - In Reply: We thank Schlapbach and MacLaren for their letter and comments on our article.1Staphylococcus aureus infections are the most common cause for admission to a pediatric intensive care unit for treatment of sepsis.2 We agree that vancomycin use as a risk factor for mortality in our study1 might in fact represent severity of disease rather than a problem with the antibiotic as such. We also agree that robust treatment protocols for S aureus–associated sepsis are urgently required. However, the evidence base to inform such protocols is sorely lacking. Important questions about the epidemiology and clinical treatment of staphylococcal bacteremia and sepsis remain, including optimal choice and duration of antibiotic therapy, benefit from combination therapy or antitoxin therapy, timing of intravenous to oral stepdown, and the role of further investigations such as echocardiography in children.

    UR - http://www.scopus.com/inward/record.url?scp=85015160536&partnerID=8YFLogxK

    U2 - 10.1001/jamapediatrics.2016.4689

    DO - 10.1001/jamapediatrics.2016.4689

    M3 - Letter

    VL - 171

    SP - 301

    EP - 302

    JO - JAMA Pediatrics

    JF - JAMA Pediatrics

    SN - 1072-4710

    IS - 3

    ER -